Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +336.03%
#4 aPriori aPriori +129.63%
#5 Bedrock Bedrock +71.69%
#6 Cysic Cysic +50.00%
#7 Prom Prom +41.40%
#8 Playnance Playnance +35.14%
#9 COTI COTI +31.27%
#10 Bitway Bitway +27.79%
Coin of the day
Wrapped One Wrapped One
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Sanofi Sanofi

Sanofi

SAN
Classement en actions #216
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Prix de l'action
$89.46
Capitalisation boursière
$107.41B
Changement (1 jour)
0.03%
Changement (1 an)
-6.17%
Pays
FR
Échange Sanofi (SAN)

Catégorie

Healthcare
Ratio P/E pour Sanofi (SAN)
Ratio P/E au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Sanofi, le ratio P/E actuel (TTM) est de 0. À la fin de l’année 2026, le P/E de l’entreprise était de 0.
Historique du ratio P/E pour Sanofi de 2026 à 2026
Ratio P/E à la fin de chaque année
Année Ratio P/E Changez
Pas assez de données pour les dates fournies.
Ratio P/E pour des entreprises similaires ou concurrentes
Entreprise P/E Ratio Différence du P/E Ratio Pays
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 40.73 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 29.64 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 123.01 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 36.58 -
US
Comment lire un P/E ratio ?

Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.

Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.

Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.